MOTION supports ibandronic acid in postmenopausal osteoporosis

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1611, 2007-01, pp. : 17-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Roche and GlaxoSmithKline have launched IV ibandronic acid [Bonviva] for postmenopausal osteoporosis in the UK

By  

Inpharma, Vol. 1, Iss. 1536, 2006-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

IV ibandronic acid an upcoming DIVA on the osteoporosis stage

By  

Inpharma, Vol. 1, Iss. 1495, 2005-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Weekly ibandronic acid prevents postmenopausal bone loss

By  

Inpharma, Vol. 1, Iss. 1406, 2003-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Osteoporosis treatment: why ibandronic acid?

By Rossini Maurizio   Orsolini Giovanni   Adami Silvano   Kunnathully Vidya   Gatti Davide  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 10, 2013-07 ,pp. : 1371-1381

Informa Healthcare

Access to resources Recommend Favorite

Clodronic Acid in the Treatment of Postmenopausal Osteoporosis

By Tanakol Refik  

Clinical Drug Investigation, Vol. 27, Iss. 6, 2007-01 ,pp. : 419-433

Adis International

Access to resources Recommend Favorite